Linagliptin (Trajenta®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000339
English
Authors' recommendations:
Linagliptin (Trajenta®) is not recommended for use within NHS Wales for the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as:
Monotherapy:
in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.
Combination therapy:
in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.
in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control
The evidence presented in the submission was insufficiently robust for AWMSG to recommend its use.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=190631&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Linagliptin
- Dipeptidyl-Peptidase IV Inhibitors
- Hypoglycemic Agents
- Diabetes Mellitus, Type 2
- Metformin
- Drug Therapy, Combination
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.